AveXis
develops and commercializes gene therapies for the treatment of neurological genetic disorders... Read moreAveXis
develops and commercializes gene therapies for the treatment of neurological genetic disorders... Read more
CEO
Add
2010
PrivateAcquired by Novartis AG
News
Sep 03, 2020
CompanyNews HQ
AveXis: AveXis renamed Novartis Gene Therapies, signifying the growing importance of gene therapy to Novartis corporate strategy
Aug 11, 2020
Manufacturing Chemist
AveXis: Catalent receives FDA approval as an additional manufacturing site for AveXis' Gene Therapy
May 29, 2020
Pharamceutical Technology
AveXis: Novartis' AveXis agrees to manufacture US researcher Covid-19 vaccine
May 28, 2020
Contract Pharma
AveXis: AveXis Enters Mfg. Pact for Novel Genetic COVID-19 Vax
May 19, 2020
The Pharma Letter
AveXis: EC approval and activation of "Day One" access program for Zolgensma in SMA
Mar 26, 2020
Pharmabiz
AveXis: AveXis announces positive data from phase 1/2 STRONG study of AVXS─101 IT in older patients with SMA Type 2
Mar 25, 2020
BioPortfolio
AveXis: AveXis Zolgensma gene therapy yields desired results in SMA trials
Mar 24, 2020
MarketScreener
AveXis: Zolgensma� data shows rapid, significant, clinically meaningful benefit in SMA including prolonged event-free survival, motor milestone achievement and durability now up to 5 years post-dosing
Mar 24, 2020
FE Investegate
AveXis: NOVARTIS AG CHF0.50(REGD) : AveXis presents AVXS-101 IT data demonstrating remarkable increases in HFMSE scores and a consistent clinically meaningful response in older patients with SMA Type 2
Mar 23, 2020
FirstWord Pharma
AveXis: Zolgensma data shows rapid, significant, clinically meaningful benefit in SMA including prolonged event-free survival, motor milestone achievement and durability now up to 5 years post-dosing
AveXis Competitors
1
2
3
4
5
6
7
8
9
10